India’s home-grown Covaxin vaccine is 81% effective against Covid-19, according to early data released Wednesday.
The vaccine was jointly developed by the company Bharat Biotech and the government-run Indian Council of Medical Research.
The clinical trial involved 25,800 participants between 18 and 98 years old, according to Bharat Biotech. The efficacy figure is based on an early analysis of 43 Covid-19 cases. Some 36 cases occurred in participants who got a placebo, compared to seven participants who got the vaccine.
Data indicates the vaccine can also effectively combat the variant first spotted in the UK, according to an analysis by India’s National Institute of Virology.
“Today is an important milestone in vaccine discovery, for science and our fight against coronavirus,” said Bharat Biotech chairman Dr. Krishna Ella. “Covaxin demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants.”
About the vaccine: Covaxin is a two-dose vaccine. It is the first Covid-19 vaccine that has been developed in its entirety in India.
More 40 countries have expressed their interest in Covaxin, including Mongolia, Myanmar, Sri Lanka, the Philippines, Bahrain, Oman, Maldives and Mauritius.